Provided by Tiger Fintech (Singapore) Pte. Ltd.

REMEGEN

85.450
+0.9501.12%
Volume:2.80M
Turnover:238.41M
Market Cap:48.16B
PE:-28.59
High:87.000
Open:83.200
Low:82.700
Close:84.500
52wk High:126.600
52wk Low:11.520
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.58
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.989
ROE:-40.42%
ROA:-9.72%
PB:18.96
PE(LYR):-28.59
PS:19.74

Loading ...

REMEGEN (09995): China's CDE Grants Breakthrough Therapy Designation to RC148 for Non-Small Cell Lung Cancer Treatment

Stock News
·
Aug 19

BUZZ-RemeGen's HK shares climb to 3-1/2-year high on Santen's licence deal

Reuters
·
Aug 19

Stock Track | REMEGEN Soars 5.04% Following Major Licensing Deal and Share Transfer

Stock Track
·
Aug 19

REMEGEN (09995) Shareholder Transfers Shares from Stock Connect (Shanghai) to HSBC Hong Kong Shanghai, Transfer Value HK$784 Million

Deep News
·
Aug 19

CICC Raises REMEGEN (09995) Target Price to HK$95.34, Maintains "Outperform" Rating

Stock News
·
Aug 18

Hong Kong Stocks Movement | REMEGEN (09995) Surges Over 5% Again as Telitacicept Phase III Clinical Results Show Promise, RC148 Enters Global Clinical Development

Stock News
·
Aug 18

CICC: Maintains Outperform Rating on REMEGEN (09995), Raises Target Price to HK$95.34

Stock News
·
Aug 15

REMEGEN (09995): Telitacicept (Brand Name: Taiai) Achieves Primary Endpoint in China Phase III Clinical Trial for Primary Sjögren's Syndrome Treatment

Stock News
·
Aug 14

HK Movers | Biotech Shares Soar. RemeGen up 16%; JW Therapeutics up 10%; Junshi Bio up 6%

Tiger Newspress
·
Aug 14

Stock Track | REMEGEN Soars 15.63% as Key Drug Achieves Primary Endpoint in Phase III Trial

Stock Track
·
Aug 14

Hong Kong Stock Market Preview | Tencent (00700) Q2 Revenue Up 15% YoY, M2 Balance at End of July Up 8.8% YoY

Stock News
·
Aug 14

China Drug Administration Accepts Junshi's Application to Combine Toripalimab With RemeGen's Drug; Junshi Shares Down 1%, RemeGen Down 3%

MT Newswires Live
·
Aug 11

HK$730 Billion Southbound Capital Reshapes Hong Kong Market: Dual Themes of High Dividends and Hard Tech Dominate H1 2025

Stock Track
·
Jul 15

HK Movers | Pharma Stocks Shine. Luye Pharma up 8%; Hua Medicine, Hengrui Pharma up 7%; Sino Biopharm, Fudan Zhangjiang up over 3%

Tiger Newspress
·
Jul 09

HK Movers|Biotech Stocks Gained. RemeGen, Junshi Bio And TigerMed Up 3%; Laekna And JW Therap Up 1%

Tiger Newspress
·
Jul 08

HK Movers|HK Innovative Drug Concept Stocks Rose. Biostar Up 15%; Akeso Up 11%; SKB Bio And Innovent Bio Up More Than 7%

Tiger Newspress
·
Jul 03

Hong Kong Stocks Shine in 25H1: Laopu Gold Soars 321%; Pop Mart Stock Triples

Tiger Newspress
·
Jul 02

RemeGen Grants Development, Sale Rights to Vor Biopharma for Myasthenia Gravis Drug; Shares Plunge 17%

MT Newswires Live
·
Jun 26

Lu Thai Textile Books 81 Million Yuan Profit From RemeGen Stake Sale

MT Newswires Live
·
Jun 26

HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept

Tiger Newspress
·
Jun 26